Combination therapy with targeted 4-1BB (CD137) agonists/anti-FAP binding domain and anti-CEA/anti-CD3 bispecific antibody

Patent metadata

Field	Value
Publication number	US-12565530-B2
Application number	US-202318166783-A
Country	US
Kind code	B2
Filing date	Feb 9, 2023
Priority date	Dec 19, 2016
Publication date	Mar 3, 2026
Grant date	Mar 3, 2026

Abstract

The present invention relates to combination therapies employing tumor targeted anti-CEA/CD3 bispecific antibodies and/or agents blocking PD-L1/PD-1 interaction in combination with 4-1BB (CD137) agonists, in particular 4-1BBL trimer containing antigen binding molecules that also target FAP, the use of these combination therapies for the treatment of cancer and methods of using the combination therapies.

First claim

The invention claimed is:

1 . A method for treating cancer in a subject, wherein the method comprises administering to the subject an effective amount of a T-cell activating anti-carcinoembryonic antigen (CEA)/anti-CD3 bispecific antibody and an effective amount of a 4-1BB agonist that binds to 4-1BB comprising at least one antigen binding domain capable of specific binding to fibroblast activation protein (FAP),
wherein said treating comprises alleviating symptoms of the cancer, diminishing pathological consequences of the cancer, delaying progression of the cancer, decreasing the rate of disease progression of the cancer, amelioration or palliation of the disease state of the cancer, remission of the cancer, or improving prognosis of the cancer; and wherein the at least one antigen binding domain capable of specific binding to FAP comprises:
a heavy chain variable region (V H FAP) comprising (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:15, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:16, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:17, and
a light chain variable region (V L FAP) comprising (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:18, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:19, and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO:20; and
wherein the 4-1BB agonist that binds to 4-1BB comprises a first polypeptide and a second polypeptide that are linked to each other by a disulfide bond,
wherein the first polypeptide comprises the amino acid sequence of SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, or SEQ ID NO:32 and the second polypeptide comprises the amino acid sequence of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, or SEQ ID NO:8.

2 . The method of claim 1 , wherein the T-cell activating anti-CEA/anti-CD3 bispecific antibody comprises a first antigen binding domain comprising a heavy chain variable region (V H CD3) and a light chain variable region (V L CD3); and a second antigen binding domain comprising a heavy chain variable region (V H CEA) and a light chain variable region (V L CEA).

3 . The method of claim 2 , wherein the second antigen binding domain comprises a heavy chain variable region (V H CEA) CDR-H1 comprising the amino acid sequence of SEQ ID NO:41, CDR-H2 comprising the amino acid sequence of SEQ ID NO:42, and CDR-H3 comprising the amino acid sequence of SEQ ID NO:43, and a light chain variable region (V L CEA) CDR-L1 comprising the amino acid sequence of SEQ ID NO: 44, CDR-L2 comprising the amino acid sequence of SEQ ID NO: 45, and CDR-L3 comprising the amino acid sequence of SEQ ID NO: 46.

4 . The method of claim 2 , wherein the second antigen binding domain comprises a heavy chain variable region (V H CEA) comprising the amino acid sequence of SEQ ID NO:47 and a light chain variable region (V L CEA) comprising the amino acid sequence of SEQ ID NO: 48.

5 . The method of claim 1 , wherein the at least one antigen binding domain capable of specific binding to FAP comprises a heavy chain variable region (V H FAP) comprising the amino acid sequence of SEQ ID NO:23 and a light chain variable region (V L FAP) comprising the amino acid sequence of SEQ ID NO:24.

6 . The method of claim 1 , wherein the 4-1BB agonist comprising at least one antigen binding domain capable of specific binding to FAP comprises:
(a) a heavy chain variable region (V H FAP) comprising the amino acid sequence of SEQ ID NO:23 and a light chain variable region (V L FAP) comprising the amino acid sequence of SEQ ID NO:24, and (b) a first polypeptide and a second polypeptide that are linked to each other by a disulfide bond, wherein the first polypeptide comprises the amino acid sequence of SEQ ID NO:29 and the second polypeptide comprises the amino acid sequence of SEQ ID NO:5.

7 . The method of claim 1 , wherein the 4-1BB agonist comprising at least one antigen binding domain capable of specific binding to FAP comprises a first heavy chain comprising the amino acid sequence of SEQ ID NO:65, a first light chain comprising the amino acid sequence of SEQ ID NO:66, and a second heavy chain comprising the amino acid sequence of SEQ ID NO:67 and a second light chain comprising the amino acid sequence of SEQ ID NO:68.

8 . The method of claim 1 , wherein the T-cell activating anti-CEA/anti-CD3 bispecific antibody comprises the polypeptide sequence of SEQ ID NO:61, the polypeptide sequence of SEQ ID NO:62, the polypeptide sequence of SEQ ID NO:63 and the polypeptide sequence of SEQ ID NO:64.

9 . The method of claim 1 , wherein the T cell-activating anti-CEA/anti-CD3 bispecific antibody comprises a polypeptide comprising the amino acid sequence of SEQ ID NO: 61, a polypeptide comprising the amino acid sequence of SEQ ID NO: 62, a polypeptide comprising the amino acid sequence of SEQ ID NO: 63 and a polypeptide comprising the amino acid sequence of SEQ ID NO: 64 and wherein the 4-1BB (CD137) agonist comprises a first heavy chain amino acid sequence of SEQ ID NO:65, a first light chain comprising the amino acid sequence of SEQ ID NO:66, a second heavy chain comprising the A amino acid sequence of SEQ ID NO:67 and a second light chain comprising the amino acid sequence of SEQ ID NO:68.

Assignees

• Hoffmann La Roche

Inventors

• Bacac Marina
• Claus Christina
• Ferrara Koller Claudia
• Klein Christian
• Lang Sabine
• Levitski Viktor
• Umaña Pablo

Classifications

• C07K16/2863

  against receptors for growth factors, growth regulators · CPC title

• C07K16/40

  against enzymes · CPC title

• C07K2317/565

  Complementarity determining region [CDR] · CPC title

• C07K2317/31

  multispecific · CPC title

• C07K16/3007

  Carcino-embryonic Antigens · CPC title